Phase 1/2 Study to Describe the Safety and Immunogenicity of a #COVID-19 #RNA #Vaccine Candidate (#BNT162b1) in Adults 18 to 55 Years of Age: Interim Report https://t.co/SGyEsXjY7j. 
$BNTX $PFE  #BioNTech #Pfizer #BNT162 #SARSCoV2 #COVID19 #vaccines